SLDB FY 2022 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-40.6% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$106M-1315.2% margin

Net Income

-$86M-1062.3% margin

EPS (Diluted)

$-10.10

Cash Flow

Operating Cash Flow

-$98M

Free Cash Flow

-$101M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$260M

Total Liabilities

$49M

Stockholders' Equity

$212M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$14M	-40.6%
Gross Profit	$8M	$14M	-40.6%
Operating Income	-$106M	-$72M	-47.3%
Net Income	-$86M	-$72M	-19.1%